semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-95.0,  Clostridium Difficile Symptomatic recurrent C. difficile infection identified by positivity of C. difficile toxin in stools (ELISA) Possibility to undergo standard antimicrobial therapy for recurrent C. difficile infection Approval of informed consent Possibility to undergo protocol diagnostic and therapeutic procedures Stool negativity for parasites Stool negativity for Salmonella spp., Shigella spp., Yersinia enterocolitica, Campylobacter, Streptococcus agalactiae, Staphylococcus aureus, enteropathogenic Escherichia coli and other microorganisms except for C. difficile Blood negativity for: Hepatitis A virus-Immunoglobulin M, HBsAg, Anti-Hepatitis C Virus, Anti-Human Immunodeficiency Virus1-2, venereal disease reaction level (VDRL)  Subjects <18 years old Main comorbidities Prior colectomy Negativity of C. difficile toxin in stools High risk of post-colonoscopy complications Other main gastrointestinal diseases (es. Crohn's disease or ulcerative colitis) Stool positivity for parasites Stool positivity for Salmonella spp., Shigella spp., Yersinia enterocolitica, Campylobacter, Streptococcus agalactiae, Staphylococcus aureus, enteropathogenic Escherichia coli and other microorganisms except for C. difficile Blood positivity for: Hepatitis A virus-Immunoglobulin M, HBsAg, Anti-Hepatitis C Virus, Anti-Human Immunodeficiency Virus1-2, venereal disease reaction level (VDRL) Pregnancy or breastfeeding
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Ulcerative Colitis Diagnosis of ulcerative colitis (UC) established at least 3 months prior to randomization (Day 1) Moderately to severely active UC as determined by the MCS Naive to treatment with TNF inhibitor therapy An inadequate response, loss of response, or intolerance to prior corticosteroid and/or immunosuppressant treatment Background UC therapy may oral 5-aminosalisylate (5-ASA), budesonide, oral corticosteroids, probiotics, azathioprine (AZA), 6-mercaptopurine (6MP), or methotrexate (MTX) if doses have been stable for AZA, 6-MP, MTX: 8 weeks immediately prior to randomization ASA: 4 weeks immediately prior to randomization Corticosteroids: 4 weeks immediately prior to randomization; if corticosteroids are being tapered, dose has to be stable for at least 2 weeks prior to randomization Use of highly effective contraception method as defined by the protocol Have received a colonoscopy within the past year or be willing to undergo a colonoscopy in lieu of a flexible sigmoidoscopy at screening  Related to Inflammatory Bowel Disease Prior extensive colonic resection, subtotal or total colectomy, or planned surgery for UC Past or present ileostomy or colostomy Diagnosis of indeterminate colitis Suspicion of ischemic colitis, radiation colitis, or microscopic colitis Diagnosis of toxic megacolon within 12 months of initial screening visit Any diagnosis of Crohn's disease Past or present fistula or abdominal abscess A history or current evidence of colonic mucosal dysplasia Patients with any stricture (stenosis) of the colon
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Graft Versus Host Disease Participants must meet the following on screening examination to be eligible to participate in the study Participants must have acute Graft-Versus-Host Disease (GVHD) of the lower gastrointestinal tract as defined by the clinical impression of the treating physician, requiring systemic treatment. Minimum for GI GVHD includes diarrhea of greater than 500 mL/day. Biopsy of the GI tract is required for study entry and must confirm the diagnosis of acute GVHD. Stool samples to rule out infectious causes of diarrhea, including norovirus, Clostridium difficile and other clinically indicated infections must also be negative. includes Acute GVHD developing after allogeneic hematopoietic stem cell transplantation (HSCT) using bone marrow, peripheral blood stem cells, or umbilical cord blood. Recipients of non-myeloablative, reduced intensity and myeloablative transplants are eligible Patients who develop acute GVHD after donor lymphocyte infusion (DLI) are eligible There is no specified time window after day 0 of transplant as acute GVHD is only defined by clinical manifestations Patients must have experienced neutrophil engraftment after HSCT as defined by absolute neutrophil counts ≥ 500 / µL × 3 consecutive measurements. Absolute neutrophil count (ANC) should be calculated using the standard formula (Neut + Bands)(WBC × 101) The presence of hepatic, upper GI and/or cutaneous acute GVHD is permitted Steroids can be started up to 7 days prior to the administration of natalizumab Age ≥ 18 Ability to understand and the willingness to sign a written informed consent document  Participants who exhibit any of the following conditions at screening will not be eligible for admission into the study Patients with the entity of Acute/Chronic GVHD overlap syndromes Requiring mechanical ventilation Vasopressor requirement Concurrent hepatic veno-occlusive disease (VOD) based on clinical examination Karnofsky performance status < 30 Participants may not be receiving any other study agents for at least 7 days prior to enrollment Prior use of natalizumab for any reason is not allowed Pregnant women are excluded from this study because of the potential teratogenic effects of natalizumab. Because natalizumab enters breast milk, and the effect is unknown in infants, breastfeeding should be discontinued if the mother is treated with natalizumab
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 20.0-999.0,  Clostridium Difficile Inpatients who have symptoms of CDAD as defined by (1)Diarrhea: with ≥4 unformed bowel movements (or ≥200 mL unformed stool for subjects having rectal collection devices) and (2)Presence of either toxin A and/or B of C. difficile in the stool Subjects who have not received antibacterials (vancomycin, metronidazole, et.al.) aiming at CDAD treatment before the study  Life-threatening or fulminant CDAD Ileus paralytic or toxic megacolon Likelihood of death before the completion of study from any cause Concurrent use of oral vancomycin, metronidazole, et.al. aiming at the treatment of CDAD The anticipated need to continue other antibacterials for a period exceeding seven days from providing the informed consent Subjects who in the opinion of the investigator require other drugs to control diarrhea Need of change in dosage regimen of opiates during the study period Need of change in dosage regimen of probiotic products during the study period History/complications of ulcerative colitis or Crohn's disease Multiple occurrences of CDAD within the past three months
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 20.0-999.0,  Hypotension of Hemodialysis Hypotension Estimated Dry Weight Myocardial Injury Arrhythmia shall consist of the following Age ≥ 20 years old Speaks and understands English, Spanish or Chinese Provides Informed Consent Patients with 20% intradialytic hypotensive events over the last two months  for both groups Unstable hemodialysis patients per judgment of the clinician prior to the start of the treatment Patients unable to have blood pressure cuff measured on the upper arm Inability to wear monitor on forehead Patients treated with sodium or ultrafiltration profiling and the patient's nephrologist is unwilling to alter this for the study treatments Patients unwilling to shave the anterior chest Patients with active infection of the upper chest wall tissue Patients with a deep brain stimulator, as it may disrupt the quality of the ECG data Patients who are unwilling to take short showers versus bathing during the 7 day period  Patients who require intradialytic testing (ie transonic) during the monitored treatment
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 55.0-999.0,  Clostridium Difficile Diarrhea Inpatients >55 Proton Pump inhibitor / Histamine-2 Blocker On broad spectrum antibiotics (Zosyn and/or Ciprofloxacin). These two antibiotics are selected based on current hospital formulary/use Anticipated hospital stay >48 hours Mental capacity (able to give informed written consent)  Admission for CDI Existing diarrhea at admission Passed prophylactic window (>48 hours on broad spectrum antibiotics) Unable to take PO at the time of evaluation for study entry No more than 14 days of broad spectrum antibiotics anticipated Medications with serious interactions/contraindications to that would be taken together with metronidazole (ex. Warfarin, disulfiram, phenytoin, calcineurin inhibitors) Inflammatory Bowel Disease Admission for colonic bowel surgery or h/o total/Subtotal colectomy) Hospice Mortality expected <7days
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Clostridium Difficile Infection Hospitalized patient Patient diagnosed with CDI  Patient already included in this study Patient is taking part in a clinical trial in the field of CDI
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 0.0-17.0,  Clostridium Difficile-associated Diarrhea (CDAD) Subject is diagnosed with CDAD according to local diagnostic criteria. As a minimum there must be positive detection, within 72 hours prior to randomization, of either toxin A and/or toxin B in stool or positive detection of toxigenic C. difficile in stool and Subject from Birth to < 2 years: watery diarrhea in the 24 hours prior to screening Subject ≥ 2 years to < 18 years: ≥ 3 unformed bowel movements in the 24 hours prior to screening Male and female subjects aged from birth to < 18 years: Note that in the United States of America subjects can only be included if aged ≥ 6 months to < 18 years For subjects < 5 years: Negative rotavirus test Female subject of childbearing potential must have a negative urine pregnancy test at Screening, and must abstain from sexual activity for the duration of the study, or must use two forms of birth control (at least one of which must be a barrier method) starting at Screening and throughout the study period and for 28 days after the final study drug administration Female subject must not be breastfeeding at Screening or during the study period, and for 28 days after the final study drug administration  below) Concurrent use of metronidazole, oral vancomycin or any other antibiotic treatments for CDAD. If the investigator feels the clinical imperative is to begin treatment before knowing the laboratory result for toxigenic C. difficile, up to four doses but no more than 24 hours of treatment with metronidazole, oral vancomycin or any other effective treatment for CDAD are allowed Subject has pseudomembranous colitis, fulminant colitis, toxic megacolon or ileus Subject has a history of inflammatory bowel disease (e.g., ulcerative colitis or Crohn's disease etc.) Subject has diarrhea caused by an agent other than C. difficile (e.g. infections, infestations, drugs etc.) Subject has known hypersensitivity to fidaxomicin, vancomycin or their excipients or to teicoplanin Subject has received an investigational therapy within 28 days, prior to Screening, with the exception of studies with primary treatment for cancer without novel Investigational Medicinal Product (IMP) and which do not affect the assessment of diarrhea
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-90.0,  Diverticulitis Diverticulosis Diverticular Disease Groups A and B. Patients with acute diverticulitis patients presenting to A&E at King's College Hospital with new onset abdominal pain, with or without a known diagnosis of diverticulitis Groups C and D. Patients with asymptomatic diverticulosis and normal controls Patients being assessed through the 2ww Colorectal Cancer pathway with a chief complaint of fresh PR bleeding and no other 'red flag' symptoms, who are not overly anxious over their diagnosis as assessed by a physician outside the study team  Groups A and B. Patients with acute diverticulitis Patients in extremis e.g. systolic blood pressure less than 80 on arrival or pulse greater than 115 Patients who have received antibiotics in the three months prior to presentation Vulnerable patient populations Groups C and D. Patients with asymptomatic diverticulosis and normal controls Patients with high levels of pre-test anxiety, as determined by their assessing physician, outside the study team Patients who received antibiotics for any reason in the 3 months prior to Vulnerable patient populations
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Clostridium Difficile Infection Patients with a confirmed diagnosis of CDI, as documented by diarrheal symptoms and positive stool test result for CDT or toxigenic C. difficile, or colonoscopic findings of PMC Patients and/or legal guardian willing to provide informed consent and/or informed assent or data release, according to local regulations  Patients with diarrheal symptoms caused by bacteria other than C. difficile, such as Salmonella, Campylobacter, Vibrio, Shigella, and Escherichia coli
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-90.0,  Enterocolitis Clostridium Difficile Recurrent Age > 18 and < 90 years at the time of Screening. 2. Diagnosis of at least 3 episodes of recurrent CDI, with each episode defined as presence of diarrhea (> 3 unformed stools/24 hours) associate with positive stool Clostridium difficle toxin, occurring within 3 months of each other. 3. CDI infection under symptomatic control with < 3 loose/unformed BM's per 24 h period for at least 2 consecutive days before procedure. 4. Those with ability to provide informed consent  Those with complicated CDI, defined as white blood cell>35 or <0.5 x 109/L, significant abdominal pain and distension with evidence of toxic megacolon or pseudomembranous colitis, hypotension defined as systolic blood pressure < 90 mmHg unresponsive to fluid resuscitation, end organ failure, or requiring intensive care unit admission. 2. Those with chronic diarrheal illness, such as irritable bowel syndrome or inflammatory bowel disease unless they are in remission for at least 3 months prior to enrollment
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 60.0-999.0,  Clostridium Difficile CDI is confirmed by clinical symptoms (either > 3 unformed bowel movements or ≥ 200ml of unformed stool (for subjects having rectal collection devices)) in the 24 hours prior to randomization and CDI test confirmed positive for presence of C. difficile toxin A or B in stool within 48 hr prior to randomization Subject agrees not to participate in another interventional study whilst participating in this study  Subject is taking or requiring to be treated with prohibited medications Subject has received more than one day of dosing of any therapy for CDI within the last 48 hours Subject has experienced more than 2 previous episodes of CDI in the 3 months prior to study enrolment Subject is unable to swallow oral study medication Subject has a current diagnosis of toxic megacolon Subject is not willing to adhere to the provisions of treatment and observation specified in the protocol Subject has been randomized into this study previously, has taken any investigational drug within 28 days or 5 half lives, whichever is longer, prior to enrollment, or is currently participating in another clinical study which may influence the assessment of efficacy and/or safety endpoints of this study, in the opinion of the Sponsor Subject has previously participated in a CDI vaccine study Subject has hypersensitivity to fidaxomicin, vancomycin or any of its components
Patient description: The patient is a 60-year-old woman admitted to the stroke department with a recent history of a second course of intravenous antibiotics for aspiration pneumonia. She is febrile and complained of abdominal pain and diarrhea (bowel movements eight times in 3 hours, large volumes of greenish, liquid stool each time). The patient's abdomen is generally tender and distend with hyperactive bowel sounds. She is febrile (38.4°C), tachycardic (113/min) and hypotensive (80/40 mmHg). The stool samples must were positive for Clostridium difficile toxin.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Clostridium Difficile Infection Diagnosis of active C. difficile infection, defined as > 3 diarrheal stools per day and a positive C. difficile PCR assay Hospitalized patient presenting with first relapse of CDI occuring between 15 and 90 days after an index episode of CDI  Pregnancy Neutropenia (absolute neutrophil count <1000/microliters) Contraindication for retention enema Food allergy not controlled in the donor diet